Results showed that patients with higher TUBA1C expression had shorter survival rates than those of the counterparts in grades II, III and IV primary glioma and grade III recurrent glioma, but not in grades II and IV recurrent glioma (Figure 1G, 1H). The gene discussed is TUBA1C; the disease is central nervous system cancer.